Fluidigm (NASDAQ:FLDM), a company that makes microfluidic systems consisting of instruments and consumables for use in life science and agricultural biotechnology research, has huge growth prospects in the emerging single-cell genomics ("SCG") market. The company has developed an innovative approach to SCG based on its microfluidics technology and going forward it aims to become a technology leader in single-cell biology.
Fluidigm recently announced that it will acquire DVS Sciences for offering its customers a comprehensive portfolio of advanced technologies across single-cell genomics and proteomics. Given that single-cell genomics is a nascent market with significant scope to grow, Fluidigm, the $1 billion company, could be a multi-bagger investing opportunity.
What is Single-Cell Genomics?
In single-cell genomics, genomic measurement technologies...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|